NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma)
Yahoo FinanceApr 26 04:12 ET
Express News | Nektar Therapeutics:Received Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement for Continued Listing on Nasdaq
Moomoo 24/7Apr 17 17:06 ET
Express News | Nektar Therapeutics Shares Hit Session Low With Volume Pickup, Last Down 8.4% at $1.53
Moomoo 24/7Apr 15 14:59 ET
NKTR, VERU and EGIO Among Mid-day Movers
Seeking AlphaApr 11 12:55 ET
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersRallybio (NASDAQ:RLYB) shares moved upwards by 70.5% to $2.78 during Thursday's regular session. The company's market cap stands at $105.1 million. Eliem Therapeutics (NASDAQ:ELYM) shares rose
BenzingaApr 11 12:31 ET
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Yahoo FinanceApr 3 11:30 ET
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN FRANCISCO, March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual
NektarMar 22 00:00 ET
Nektar Therapeutics Is Worried About This – Should You Be Worried Too?
TipRanksMar 7 01:00 ET
Nektar Therapeutics Is Maintained at Hold by Jefferies
Nektar Therapeutics Is Maintained at Hold by Jefferies
Dow JonesMar 6 09:54 ET
Express News | Jefferies Maintains Hold on Nektar Therapeutics, Raises Price Target to $1
Moomoo 24/7Mar 6 09:44 ET
Nektar Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/06/2024 13.64% Jefferies $0.5 → $1 Maintains Hold 11/20/2023 — JP Morgan Reinstates → Underweight 11/0
BenzingaMar 6 09:43 ET
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata
Nektar Therapeutics (NKTR) said Tuesday it started the phase 2b trial for rezpegaldesleukin to treat patients experiencing severe to very severe alopecia areata. The Phase 2b study will evaluate rezpe
MT NewswiresMar 5 16:04 ET
Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating
Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating.
MT NewswiresMar 5 12:49 ET
Nektar Therapeutics Announces Initiation Of Phase 2b Clinical Study Evaluating Rezpegaldesleukin In Patients With Severe To Very Severe Alopecia Areata
Nektar Therapeutics (NASDAQ:NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation of its Phase 2b clinical trial evaluating rez
BenzingaMar 5 09:09 ET
Q4 2023 Nektar Therapeutics Earnings Call
Yahoo FinanceMar 5 07:19 ET
Earnings Call: Nektar Therapeutics Unveils Drug Development Progress
InvestingMar 5 04:20 ET
Earnings Call Summary | Nektar Therapeutics(NKTR.US) Q4 2023 Earnings Conference
The following is a summary of the Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript:Financial Performance:Nektar ended the year with a strong balance sheet, having $329.4 million in cash and
moomoo AIMar 4 23:13 ET · Conference Call
Nektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Results
Yahoo FinanceMar 4 16:51 ET
Nektar Therapeutics Q4 Loss Decreases, but Misses Estimates
RTTNewsMar 4 16:18 ET
Nektar Therapeutics GAAP EPS of -$0.22 Misses by $0.01, Revenue of $23.89M Beats by $2.52M
Seeking AlphaMar 4 16:17 ET
No Data
No Data